ArticlePloS one2013
Dopamine D1 receptor gene variation modulates opioid dependence risk by affecting transition to addiction.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Pooled it
- High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial.Molecular neurobiology · 2021Trial
- The influence of dopamine receptor SNPs on substance use disorder in a Jordanian cohort.BMC research notes · 2025Article
- Predicting postoperative chronic opioid use with fair machine learning models integrating multi-modal data sources: a demonstration of ethical machine learning in healthcare.Journal of the American Medical Informatics Association : JAMIA · 2025Article
- Influence of dopamine-related genes on craving, impulsivity, and aggressiveness in Korean males with alcohol use disorder.European archives of psychiatry and clinical neuroscience · 2021Article
- Tyrosine Hydroxylase Gene Polymorphisms Contribute to Opioid Dependence and Addiction by Affecting Promoter Region Function.Neuromolecular medicine · 2020Article
- Association studies of dopamine synthesis and metabolism genes with multiple phenotypes of heroin dependence.BMC medical genetics · 2020Article
- Heroin delay discounting and impulsivity: Modulation by DRD1 genetic variation.Addiction biology · 2020Article
- History of regular nonmedical sedative and/or alcohol use differentiates substance-use patterns and consequences among chronic heroin users.Addictive behaviors · 2019Article
- An update on the safety of prescribing opioids in pediatrics.Expert opinion on drug safety · 2019Review
- Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders.Frontiers in psychiatry · 2019Review
- Gene network analysis shows immune-signaling and ERK1/2 as novel genetic markers for multiple addiction phenotypes: alcohol, smoking and opioid addiction.BMC systems biology · 2015Article
- Overlapping dopaminergic pathway genetic susceptibility to heroin and cocaine addictions in African Americans.Annals of human genetics · 2015Article
- DRD1 and DRD2 genotypes modulate processing modes of goal activation processes during action cascading.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2014Article
- Living in the moment: effects of time perspective and emotional valence of episodic thinking on delay discounting.Behavioral neuroscience · 2014Article
- Metabotropic glutamate receptor 3 is associated with heroin dependence but not depression or schizophrenia in a Chinese population.PloS one · 2014Article
- Translating the human genome to manage pediatric postoperative pain.Journal of pediatric surgical nursingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dopamine D1 receptor (DRD1) modulates opioid reinforcement, reward, and opioid-induced neuroadaptation. We propose that DRD1 polymorphism affects susceptibility to opioid dependence (OD), the efficiency of transition to OD, and opioid-induced pleasure response. We analyzed potential association between seven DRD1 polymorphisms with the following traits: duration of transition from the first use to dependence (DTFUD), subjective pleasure responses to opioid on first use and post-dependence use, and OD risk in 425 Chinese with OD and 514 healthy controls. DTFUD and level of pleasure responses were examined using a semi-structured interview. The DTFUD of opioid addicts ranged from 5 days to 11 years. Most addicts (64.0%) reported non-comfortable response upon first opioid use, while after dependence, most addicts (53.0%) felt strong opioid-induced pleasure. Survival analysis revealed a correlation of prolonged DTFUD with the minor allele-carrying genotypes of DRD1 rs4532 (hazard ratios (HR) = 0.694; p = 0.001) and rs686 (HR = 0.681, p = 0.0003). Binary logistic regression indicated that rs10063995 GT genotype (vs. GG+TT, OR = 0.261) could predict decreased pleasure response to first-time use and the minor alleles of rs686 (OR = 0.535) and rs4532 (OR = 0.537) could predict decreased post-dependence pleasure. Moreover, rs686 minor allele was associated with a decreased risk for rapid transition from initial use to dependence (DTFUD≤30 days; OR = 0.603) or post-dependence euphoria (OR = 0.603) relative to major allele. In conclusion, DRD1 rs686 minor allele decreases the OD risk by prolonging the transition to dependence and attenuating opioid-induced pleasure in Chinese.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.